Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Spiritual care for Latinx youth with type 1 diabetes (T1D) and their caregivers: qualitative analysis of focus groups.

Diabetology & metabolic syndrome·2026
Same author

Ventricular conduction is a marker for arrhythmic risk in SCN5A-E1784K overlap sodium channel disease.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Considerations on phrenic nerve and sinus node safety during superior vena cava isolation using a balloon-in-basket pulsed field ablation system.

Heart rhythm O2·2026
Same author

Integrated mapping-guided superior vena cava isolation with single-shot pulsed field ablation systems: Feasibility, workflow, and safety in a real-world patient cohort.

Heart rhythm·2026
Same author

Regression of massive left ventricular hypertrophy in Danon disease.

Acta cardiologica·2026
Same author

Initial Clinical Experience With a Novel 4D Intracardiac Echocardiographic Imaging and Guidance System in Catheter Ablation Procedures.

Journal of cardiovascular electrophysiology·2026

相关实验视频

Updated: May 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

通过使用数字化解决方案简化心房动除管理.

Jim O'Brien1, Sergio Valsecchi2, Fionnuala Seaver1

  • 1Atrial Fibrillation Institute, Mater Private Hospital, 71 Eccles Street, Dublin 7, D07 T92C, Ireland.

European heart journal. Digital health
|July 31, 2024
PubMed
概括
此摘要是机器生成的。

一个新的移动应用程序和治疗途径改善了对心房动 (AF) 导管切除的患者教育和坚持. 这种以患者为中心的方法提高了对AF管理和治疗并发症的理解.

关键词:
心房动是一种心房动.护理数字化 护理数字化导管切除 导管切除 导管切除 导管切除知识知识知识知识知识.门诊护理 门诊护理 门诊护理患者教育 患者教育患者的参与度 患者的参与度

更多相关视频

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K

相关实验视频

Last Updated: May 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K

科学领域:

  • 心脏病学 心脏病学
  • 数字健康数字健康
  • 患者教育 患者教育

背景情况:

  • 导管切除是心房动 (AF) 的标准治疗方法.
  • 有效的患者教育程序的有效性,并发症,中风风险和抗凝药非常重要.
  • 优化AF导管切除患者的管理需要解决知识差距并改善患者的坚持.

研究的目的:

  • 实施和评估以患者为中心的解决方案,整合针对AF导管切除候选人的定制治疗途径和移动应用程序.
  • 通过提高患者知识和遵守基于指南的护理来加强临床管理.

主要方法:

  • 在Mater私立医院实施了移动应用程序和定制治疗途径.
  • 该解决方案自动化了手术前评估和手术后支持,促进了患者与临床医生的沟通.
  • 从2022年9月到2023年4月,追踪了患者参与和遵守该途径的情况.

主要成果:

  • 63名患者安装了该应用程序,其中98%参与了治疗途径,81%完成了手术前的任务.
  • 平均注册到入院的时间为14天;62%的人在36天内完成了切除后的任务.
  • 报告了高患者满意度和改善了对AF,症状和抗凝血并发症的知识.

结论:

  • 基于应用程序的Ablation Solution展示了成功实施的高患者利用率和坚持性.
  • 该系统有效地提高了患者对AF及其治疗方法的理解.
  • 这种方法提供了一种有前途的方法来简化AF导管切除的管理,并提高患者的治疗结果.